Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/1297
Title: Brentuximab vedotin: targeting CD30 as standard in CTCL.
Epworth Authors: Prince, Miles
Other Authors: Gautam, Ashish
Kim, Youn
Keywords: ALCANZA Study
Cutaneous T-Cell Lymphoma
CTCL
Anti-CD30
Brentuximab Vedotin
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Issue Date: Feb-2018
Publisher: Impact Journals
Citation: Oncotarget. 2018 Feb 10;9(15):11887-11888
Abstract: Editorial
URI: http://hdl.handle.net/11434/1297
DOI: 10.18632/oncotarget.24472
URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844715/
PubMed URL: https://www.ncbi.nlm.nih.gov/pubmed/29552279
ISSN: 1949-2553
Journal Title: Oncotarget
Type: Letter
Copyright: 2018 Prince et al.
Affiliated Organisations: Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum
The University of Melbourne, VIC, Australia
Appears in Collections:Cancer Services

Files in This Item:
File Description SizeFormat 
Prince et al 2018.pdf662.04 kBAdobe PDFView/Open


Items in EKB are protected by copyright, with all rights reserved, unless otherwise indicated.